A case of hepatocellular carcinoma (HCC): Treatment with local application of alcohol and interleukin 2 (IL-2)

Hepato-Gastroenterology

Volumn 50, Issue 53, 2003, Pages 1647-1649

  Krastev, Z ^a   Koltchakov, V ^a   Popov, D ^a   Alexiev, A ^a   Koten, J W ^b   Den Otter, W ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Alcohol; Hepatocellular carcinoma (HCC); Interleukin 2 (IL 2); Local treatment

Indexed keywords

ALCOHOL; INTERLEUKIN 2;

AGED; ARTICLE; CANCER PATIENT; CASE REPORT; CAUSE OF DEATH; CHRONIC PYELONEPHRITIS; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DRUG RESPONSE; EMPHYSEMA; FOLLOW UP; HEPATITIS C; HUMAN; INJECTION; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; STOMACH HEMORRHAGE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR VOLUME; ULTRASOUND;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; ETHANOL; FATAL OUTCOME; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; LIVER NEOPLASMS; MALE;

EID: 0141650696     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Jurgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, Battermann JJ: Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Radiat Oncol Investig 1997; 5(2):54-61.
2. Bernsen MR, Van Barlingen HJ, Van der Velden AW, Dullens HF, Den Otter W, Heintz AP: Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor dependent phenomenon. Int J Cancer 1993; 54(3):513-517.
3. Farinati F, Rinaldi M, Gianni S, Naccarato R: How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system: Cancer 2000; 89:2266-2273.
4. Lygidakis NJ, Kosmidis P, Ziras N, Parissis J, Kyparidou E: Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 1995; 15:467-472.
5. Giorgio A, Tarantino L, Mariniello N, de Stefano G, Perrotta A, Aloisio V, Voza A, Finizia L, Alaia A, Del Viscovo L: Percutaneous ethanol injection under general anesthesia for hepatocellular carcinoma: 3-year survival in 112 patients. Eur J Ultrasound 1998; 8:201-206.
6. Livraghi T, Benedini V, Lazzaroni S, Meloni F, Torzilli G, Vettori C: Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma. Cancer 1998; 1:83:48-57.
7. Tsuyuki S, Yamauchi A, Nakamura H, Kinoshita K, Gomi T, Tanaka K, Inamoto T, Yamaoka Y: Possible availability of N-acetylcysteine as an adjunct to cytokine therapy for hepatocellular carcinoma. Clin Immunol Immunopathol 1998; 88:192-198.
8. Hirofuji H, Kakumu S, Fuji A, Ohtani Y, Murase K, Tahara H: Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells. Clin Exp Immunol 1987; 68:348-356.
9. Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tancini G, Piperno A, Pozzi M, Ricci G, Conti A, Maestroni GJ: Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994; 30A:167-170.
10. Lygidakis NJ, Konstantinidou T, Pothoulakis J: Pre- and post-operative adjuvant targeting locoregional chemotherapy combined with locoregional targeting immunostimulation and surgical resection for hepatocellular carcinoma. A new promising alternative. Anticancer Res 1994; 14:1351-1355.
11. Yamamoto M, Fujii H: Optimal locoregional immunochemotherapy after tumors-mass reduction for advanced hepatocellular carcinoma. Hepatogastroenterology 1995; 42:567-577.
12. Hazama S, Oka M, Shimizu R, Yano K, Yoshino S, Iizuka N, Murakami T, Suzuki T: Intra-arterial combination immunotherapy in hepatocellular carcinoma. Gan To Kagaku Ryoho 1990; 17:1638-1642.
13. Oka M, Hazama S, Yoshino S, Shimoda K, Suzuki M, Shimizu R, Yano K, Nishida M, Suzuki T: Intra-arterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results. Cancer Immunol Immunother 1994; 38:194-200.
14. Ito T, Ikeda N, Sue K, Ukida M, Higashi T, Okamoto T, Ohsawa T, Nouso K, Watanabe A, Tsuji T: Immunotherapy using Freund's adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma. Gastroenterol Jpn 1989; 24:386-392.
15. Gandolfi L, Solmi L, Pizza GC, Bertoni F, Muratori R, De Vinci C, Bacchini P, Morelli MC, Corrado G: Intratumoural echo-guided injection of interleukin-2 and lymphokine-activated killer cells in hepatocellular carcinoma. Hepatogastroenterology 1989; 36:352-356.
16. Uchino J, Une Y, Kawata A, Wakisaka Y, Hosokawa M: Postoperative chemoimmunotherapy for the treatment of liver cancer. Semin Surg Oncol 1993; 9:332-336.